Antilipemic CAS 147098-20-2 Rosuvastatin Calcium Pharmaceutical Rosuvastatin Calcium Powder Purity Rosuvastatin Calcium

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Rosuvastatin Calcium
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Rosuvastatin Calcium
• Name: Rosuvastatin Calcium Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Antilipemic
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 147098-20-2
• Mf: C44h54caf2n6o12s2
• MW: 520.609
• Melting Point: 122ºC
• Boiling Point: 745.6 °c at 760 Mmhg
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Antilipemic CAS 147098-20-2 Rosuvastatin Calcium Pharmaceutical Rosuvastatin Calcium Powder Purity Rosuvastatin Calcium

Product Description

Product Details

Product name	Rosuvastatin Calcium
Cas number	147098-20-2
Apperance	White powder
MF	C44H54CaF2N6O12S2
MW	520.609

Rosuvastatin Calcium is the calcium salt form of rosuvastatin, a statin with antilipidemic activity. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol.   
Rosuvastatin Calcium is the calcium salt form of rosuvastatin, a statin with antilipidemic activity. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. 

Application&Function

Rosuvastatin calcium is a HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES.

Specification